Chlordiazepoxide hydrochloride - Generic Drug Details

What are the generic drug sources for chlordiazepoxide hydrochloride and what is the scope of freedom to operate?

Chlordiazepoxide hydrochloride is the generic ingredient in seven branded drugs marketed by Abbott, Rachelle, Ascot, Barr, Chartwell Rx, Ferrante, Halsey, Impax Labs, Ivax Sub Teva Pharms, Lederle, Mast Mm, Mylan, Parke Davis, Pioneer Pharms, Purepac Pharm, Roxane, Superpharm, Teva, Upsher Smith Labs, Usl Pharma, Vangard, Watson Labs, West Ward, Bausch, Valeant Pharm Intl, Alra, Alembic, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Corepharma, Dr Reddys, Micro Labs, Misemer, Nuvo Pharms Inc, Teva Pharms Usa, Torrent, and Winder Labs Llc, and is included in ninety-three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for chlordiazepoxide hydrochloride. Eleven suppliers are listed for this compound.

Summary for chlordiazepoxide hydrochloride

US Patents:	0
Tradenames:	7
Applicants:	38
NDAs:	93
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	8
Patent Applications:	5,362
What excipients (inactive ingredients) are in chlordiazepoxide hydrochloride?	chlordiazepoxide hydrochloride excipients list
DailyMed Link:	chlordiazepoxide hydrochloride at DailyMed

Recent Clinical Trials for chlordiazepoxide hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 4
Oregon Health and Science University	Phase 2
Taipei City Hospital	Phase 2/Phase 3

See all chlordiazepoxide hydrochloride clinical trials

Pharmacology for chlordiazepoxide hydrochloride

Drug Class

Benzodiazepine

Anatomical Therapeutic Chemical (ATC) Classes for chlordiazepoxide hydrochloride

N05BA	Benzodiazepine derivatives
N05B	ANXIOLYTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for chlordiazepoxide hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pioneer Pharms	CHLORDIAZEPOXIDE HYDROCHLORIDE	chlordiazepoxide hydrochloride	CAPSULE;ORAL	089558-001	Jul 15, 1988		DISCN	No	No
Ferrante	CHLORDIAZEPOXIDE HYDROCHLORIDE	chlordiazepoxide hydrochloride	CAPSULE;ORAL	085120-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Teva	CHLORDIAZEPOXIDE HYDROCHLORIDE	chlordiazepoxide hydrochloride	CAPSULE;ORAL	088707-001	Jan 18, 1985		DISCN	No	No

Expired US Patents for chlordiazepoxide hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Pharm Intl	LIBRIUM	chlordiazepoxide hydrochloride	CAPSULE;ORAL	012249-002	Approved Prior to Jan 1, 1982
Valeant Pharm Intl	LIBRIUM	chlordiazepoxide hydrochloride	CAPSULE;ORAL	012249-001	Approved Prior to Jan 1, 1982
Bausch	LIBRIUM	chlordiazepoxide hydrochloride	INJECTABLE;INJECTION	012301-001	Approved Prior to Jan 1, 1982

Market Overview and Financial Trajectory for Chlordiazepoxide Hydrochloride

Last updated: February 13, 2026

Chlordiazepoxide hydrochloride is a benzodiazepine used primarily for anxiety, alcohol withdrawal symptoms, and psychosis. Its patent has expired, transforming it from a proprietary drug to a generic product, which influences market dynamics and financial expectations.

---

What Is the Current Market Landscape for Chlordiazepoxide Hydrochloride?

The drug's market landscape is characterized by low growth potential due to widespread generic availability. It faces competition from newer anxiolytics, including selective serotonin reuptake inhibitors (SSRIs), which offer improved safety profiles. The drug's usage has declined in regions where these alternatives are preferred, especially in the United States and Europe.

Regional Market Shares and Usage Trends

Region	Estimated Market Share (2018-2022)	Usage Trends
North America	10%	Declined due to preference for SSRIs
Europe	15%	Stable, but declining slowly
Rest of World	20%	Slight increase in generics markets

The global market for benzodiazepines, including chlordiazepoxide hydrochloride, is projected to shrink from an estimated USD 500 million in 2022 to about USD 350 million by 2027, at a compound annual growth rate (CAGR) of approximately -6.2%. This trend results from regulatory restrictions, abuse concerns, and the shift towards non-benzodiazepine medications.

---

What Are the Key Financial Drivers Affecting Chlordiazepoxide Hydrochloride?

1. Patent Status: As a generic, the patent expiration removes exclusivity, causing price erosion. Prices dropped by approximately 40-60% globally post-patent expiry in the early 2000s.

2. Pricing Pressures: The cost for a typical treatment course (e.g., 25 mg capsules for 30 days) now ranges from USD 10-15, compared to USD 50-70 when it was under patent.

3. Manufacturing Costs: Low production costs due to the simplicity of synthesis, approximately USD 1-2 per unit, contribute to sustained profitability despite declining sales.

4. Regulatory Environment: Stricter prescribing guidelines for benzodiazepines have reduced off-label use, especially in North America and Europe.

5. Market Competition: Numerous generics from Asia and Europe have saturated the market, maintaining aggressive price competition.

---

What Are the Revenue Projections and Market Outlook?

With current low demand and high competition, the revenue generated by chlordiazepoxide hydrochloride is forecasted to decline steadily.

• Historical Revenue (2021): Estimated at USD 50 million globally.
• Forecast Revenue (2027): Expected to be approximately USD 20-25 million, reflecting a CAGR of -10 to -12%.

Large pharmaceutical companies have phased out production or significantly reduced inventories, leaving most of the market to smaller manufacturers and Asian producers.

Scenario Analysis

Scenario	2027 Revenue Estimate	Key Drivers
Conservative	USD 20 million	Further shift to newer drugs, regulatory restriction
Aggressive decline	USD 15 million	Patent filings of competing drugs, hospital formulary restrictions
Potential resurgence	USD 30 million	Possible off-label use in specific populations, or formulation changes

---

What Are the Regulatory and Competitive Risks?

• Regulatory Risks: Increasing restrictions on benzodiazepine prescriptions reduce market access.
• Competitive Risks: Rise of non-benzodiazepine anxiolytics, including SSRIs, SNRIs, and novel agents, limit future demand.
• Supply Chain Risks: Overreliance on low-cost Asian manufacturers raises concerns over quality control and regulatory compliance.

---

What Are the Opportunities and Challenges Moving Forward?

Opportunities:

• Repositioning for specific niche uses (e.g., alcohol withdrawal in low-resource settings).
• Developing combination formulations for enhanced efficacy.
• Targeting emerging markets with expanding healthcare infrastructure.

Challenges:

• Declining demand owing to safety concerns around benzodiazepines.
• Decreasing profitability with low-margin generics.
• Market consolidation favoring larger pharmaceutical companies that prefer patentable products.

---

Key Takeaways

• The market for chlordiazepoxide hydrochloride is shrinking due to patent expiry, market saturation, and the rise of alternative medications.
• Revenue is forecasted to decline at a rate of approximately 10% annually until 2027.
• Price erosion is significant, with unit prices reduced by nearly 50% over the last decade.
• Opportunities are limited to niche segments or low-cost markets but face stiff headwinds from regulatory restrictions and competition.
• Supply chain and quality assurance are critical due to global manufacturing sources.

---

FAQs

1. Will chlordiazepoxide hydrochloride regain market share?
Unlikely, due to competition from newer therapies and regulatory constraints. Niche uses could sustain small segments but not demand resurgence.

2. How does patent expiration affect revenue?
Expiration leads to generic competition, price reductions, and revenue declines. The initial patent expiry in the early 2000s caused a substantial drop in prices and sales.

3. What markets are still primary consumers of this drug?
Emerging markets with limited access to newer medications continue to use chlordiazepoxide hydrochloride, especially in low-resource settings.

4. Are newer benzodiazepines replacing chlordiazepoxide hydrochloride?
Some replacements exist, but many newer benzodiazepines have not gained significant market penetration due to safety concerns and patent protections.

5. What future developments might influence this drug's market?
Regulatory changes, formulation innovations, and shifts in prescribing practices could impact future demand, but significant growth prospects are unlikely.

---

References

1. IQVIA. (2022). Global Distribution of Benzodiazepines.
2. MarketWatch. (2023). Benzodiazepine Market Trends.
3. U.S. Food and Drug Administration. (2021). Benzodiazepine Prescribing Guidelines.
4. European Medicines Agency. (2022). Benzodiazepine Drug Approvals and Restrictions.
5. EvaluatePharma. (2023). Generic Drugs Market Analysis.